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ABSTRACT
The association between schizophrenia and tobacco smoking has been described in more than1000 articles, many with
inadequate methodology. The studies on this association can focus on: 1) current smoking, ever smoking or smoking cessation;
2) non-psychiatric controls or controls with severe mental illness (e.g., bipolar disorder); and 3) higher smoking frequency or
greater usage in smokers. The association with most potential for genetic studies is that between ever daily smoking and
schizophrenia; it may reflect a shared genetic vulnerability. To reduce the number of false-positive genes, we propose a threestage approach derived from epidemiological knowledge. In the first stage, only genetic variations associated with ever daily
smoking that are simultaneously significant within the non-psychiatric controls, the bipolar disorder controls and the
schizophrenia cases will be selected. Only those genetic variations that are simultaneously significant in the three hypothesis
tests will be tested in the second stage, where the prevalence of the genes must be significantly higher in schizophrenia than in
bipolar disorder, and significantly higher in bipolar disorder than in controls. The genes simultaneously significant in the
second stage will be included in a third stage where the gene variations must be significantly more frequent in schizophrenia
patients who did not start smoking daily until their 20s (late start) versus those who had an early start. Any genetic approach to
psychiatric disorders may fail if attention is not given to comorbidity and epidemiological studies that suggest which
comorbidities are likely to be explained by genetics and which are not. Our approach, which examines the results of
epidemiological studies on comorbidities and then looks for genes that simultaneously satisfy epidemiologically-suggested sets
of hypotheses, may also apply to the study of other major illnesses.
Key words: tobacco, nicotine, schizophrenia, bipolar disorder, severe mental illness, genes

3
This article proposes a study approach to investigating the genetics of the association between schizophrenia and
tobacco smoking based on results from the epidemiological literature. After an introduction, a short section that summarizes
the various types of published data follows. The next two sections describe the association of schizophrenia with higher
frequency and with higher intensity of smoking. The section describing the proposed study approach is followed by two
sections placing the association between schizophrenia and smoking in the context of other psychiatric comorbidities: the
association between nicotine and alcohol addiction, and the association between nicotine and drug addiction. Then, a
description of how our study approach may take advantage of these other comorbidities follows.
INTRODUCTION
This introduction provides the genetic expert without expertise in psychiatry with information on 1) the size and
quality of the literature on schizophrenia and smoking; 2) some epidemiological statistical concepts; 3) the concept of
addiction; 4) the concept of nicotine addiction; 5) the genetics of nicotine addiction; 6) the association between schizophrenia
and nicotine addiction; and 7) the concept of severe mental illness (SMI), which encompasses other illnesses besides
schizophrenia that are also associated with nicotine addiction, particularly bipolar disorder and major depressive disorder.
Schizophrenia and tobacco smoking literature
The literature is full of articles on the association between smoking and schizophrenia. A PubMed search on
“schizophrenia AND (smoking OR nicotine)” on July 6, 2011, produced 1,341 articles. If one is not an expert in this area, one
would think that more than 1,000 published articles would provide a good understanding of this association. We propose in this
article that, unfortunately, this is not the case. Many of the published articles include simplistic statements due to
misinterpretation of statistical associations as causal relationships. Clinicians and basic scientists may not be aware of the
limitations of the epidemiological approach and may not realize that many of the statements published in articles on the
association between schizophrenia and smoking are wrong, according to basic epidemiological principles. As a matter of fact,
it is possible that many of the articles on schizophrenia and smoking published in the 1990s in psychiatric journals would not
currently be accepted for publication by epidemiological journals as they were originally published. Many of these published
articles failed to account for cross-sectional studies’ inability to establish causation and did not correct the reported statistical
associations for confounding effects using multivariate statistics. Another problem with the information provided in the review
sections of published articles on schizophrenia and smoking is that some authors frequently tend to ignore studies that do not fit
their hypotheses and do not give proper weight to consistently replicated findings when describing the literature. As described
by Ioannidis (2005), the medical literature is full of false findings due to the publication of significant but small effects
observed in small samples.

The most important factor in establishing a scientific finding in medicine is the finding’s

replication across many independent samples. In particular, it is necessary that the finding survives the variations typically
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associated with the “noise” present in clinical research. In this regard we are quite confident that the association of
schizophrenia with tobacco smoking is a “true” finding since it is a finding that has been consistently replicated all over the
world (de Leon and Diaz 2005). However, we are not sure that many of the other findings published in the context of
schizophrenia and smoking research are trustworthy, since very few have been consistently replicated. Thus, simplistic
statements such as “smoking improves negative symptoms or antipsychotic side effects in schizophrenia patients” are not
supported by a comprehensive review of the limited literature available (de Leon et al. 2006).
Epidemiological and statistical concepts
In this article two statistical measures are used to explore associations: adjusted odds ratios (ORs), and population
attributable risks (PAR) calculated with these ORs (Bolton and Robinson 2010; Greenland and Drescher 1993). The OR is a
measure of the strength of the association between two dichotomous variables: the more different from 1 an OR is, the stronger
the association. When the 95% confidence intervals (CIs) of two ORs do not overlap, they are usually considered to be
significantly different. A multivariate method, logistic regression, allows adjusting ORs for potentially confounding variables.
Once we have an adjusted OR, if we assume that the OR measures a causal relationship between a condition and a risk factor
which is not explained by confounders, the PAR estimates the percentage reduction in the condition’s prevalence that would be
observed if the risk factor were removed from the population.
Addiction
This article uses the term “addiction” to express the compulsive nature of taking an addictive drug (Volkow and
Fowler 2000). Drug addiction is a group of chronically relapsing disorders characterized by compulsion to take the drug, loss
of control in limiting the intake, and emergence of negative emotional states when there is no access to the drug (Koob and
Volkow 2010). The current official psychiatric diagnostic system in the US is called the Diagnostic and Statistical Manual of
Mental Disorders and is a variation of the third edition published in 1980, called DSM-III (American Psychiatric Association,
1980). The current edition of the DSM continues to use the terminology “substance use disorder”, distinguishing between
abuse (pathological use) and dependence (more severe pathological use with withdrawal symptoms).
The third and subsequent DSM editions use the word “substances” to mean “nicotine”, “alcohol”, and other
substances of abuse that are usually included under the name “drugs”. The term “drug” usually refers to “illegal drugs” or
prescribed drugs used inappropriately. Thus, this article, unless it is specifically needed (e.g., “nicotine dependence”, which is
specifically defined) uses the terms “alcohol addiction”, “nicotine addiction” and “drug addiction” (referring to drugs other
than nicotine or alcohol). When we use the plural word “addictions”, we mean addiction to any of these substances (nicotine,
alcohol or other drugs) in general.
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For researchers interested in genetics, it is important to know that addiction heritability estimates are 40-60% (Volkow
and Li 2005) or 50-60% (Bierut 2011). Bierut (2011) recently described genetic vulnerability to addiction as probably
reflecting the combination of hundreds or thousands of genes of modest effects. A complex issue not completely resolved by
the literature is that genetic factors influencing the use of drugs may be different from those influencing addiction. Twin
studies suggest that initiation and early patterns of drug use are strongly influenced by social and familial environmental factors
whereas later patterns of use and levels of addiction are strongly influenced by genetic factors (Kendler et al. 2008). Even if
we accept the hypothesis that genetic factors may be much more influential in drug addictions than in drug use, an explanation
of the important role of genetic influences on addictions continues to be complex. A biological hypothesis proposes that
genetic factors are expressed once exposed to sufficient quantities of the drug over a sufficiently long period. The socially
mediated hypothesis is based on the finding that our genes play an increasing role in shaping our own social environment; it
proposes that genes may influence the selection of environments that either actively discourage or encourage drug use (Kendler
et al. 2008).
As this article focuses on the role of genetics in the association between schizophrenia and nicotine addiction, a
context for the genetic studies on the association between psychiatric disorders and addictions is in order.

In a very

comprehensive approach, Kendler and coworkers (2003; 2007) proposed a model that posits: 1) the pattern of lifetime
comorbidity of common psychiatric disorders and addictions results largely from the effects of genetic risk factors, and 2) each
addiction may have disorder-specific genetic risks.
Nicotine addiction
Epidemiological studies in the 1980s and 1990s in the US and other Western countries established that the majority of
smokers in these general populations smoke at last one cigarette per day; that is, they are daily smokers. Few people in the
general population of Western countries are considered occasional smokers. Nicotine is the most important addictive
component of tobacco smoke. Thus, daily smoking is usually considered a sign of nicotine addiction. In the general population,
initiation of daily smoking rarely occurs in the decade of one’s 20s (Nelson et al. 1998; de Leon et al. 2002a; Dierker et al.
2008). Occasional smokers do not smoke daily, appear not to have major problems (no major withdrawal signs) when they do
not smoke and, therefore, are not addicted (Shiffman 1989). “Daily smoking” is a simple and reasonable measure of nicotine
addiction in epidemiological studies in Western countries.
In underdeveloped countries, few individuals can afford daily smoking and non-daily smokers need to be included in
smoking studies; socioeconomic status needs to be carefully considered as well (Campo-Arias et al. 2006). In the US
population, progressively greater smoking restrictions have been implemented since 2000. This has led to an increase in the
proportion of non-daily smokers, who now account for one third of the US smokers in the general population (Shiffman 2009).
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Therefore, Shiffman (2009) has proposed that heavy daily smoking may only occur when smoking is not constrained by
economic, social or legal restrictions.
The DSM, which has become widely used internationally since its third edition (DSM-III), does not list “nicotine
abuse” as a possible diagnosis; only “nicotine dependence” is listed. Thus, the abuse and dependence concepts of this
classificatory system have never particularly “worked well” for nicotine addiction. The reasons may be that:

1) when

compared with other drugs, nicotine is a particularly addictive substance (Hennigfeld et al. 1991; Lopez-Quintero et al. 2011);
and 2) it is a legal substance whose uncontrolled use is very rarely associated with legal complications. In a large US
epidemiological study, Lopez-Quintero and coworkers (2011) estimated that 68% of nicotine users become dependent (versus
23% for alcohol, 21% for cocaine, and 9% for cannabis users). The DSM concepts of nicotine dependence, however, have been
used in a few epidemiological studies of the general population but not in patients with schizophrenia.
Clinicians and researchers working in smoking cessation frequently use a scale to define nicotine dependence. The
Fagerström Test for Nicotine Dependence (FTND) is the most widely used measure of nicotine dependence, which has been found
to be a reasonable predictor of success in stopping smoking (Heatherton et al. 1991). This scale has six items. However, two of the
six items, which are each scored between 0 and 3, may reflect nicotine dependence best: Item 1 (the time between waking and
smoking the first cigarette of the day), and Item 4 (the number of cigarettes smoked per day). The sum of the scores of these two
items is called the Heaviness of Smoking Index (HSI) (Heatherton et al. 1998). A high FTND or HSI score appears to be a good
indication of high nicotine dependence (de Leon et al. 2003b; Diaz et al. 2005). Institutional smoking restrictions may artificially
lower these scores (Steinberg et al. 2005).
Nicotine addiction and genetics
Genome-wide association studies (GWAS) have provided some robust findings for heavy smoking genetics in the
15q25 chromosome region, which encodes some nicotine receptor subunits (Bierut 2011).

According to twin studies,

heritability for smoking initiation has been estimated to be in males: 37% (Li et al. 2004), 31-61% (Tyndale, 2003), and 2275% (Rose et al. 2008) and in females 55% (Li et al. 2004), 32-72% (Tyndale, 2003), and 32-63% (Rose et al. 2008).
Heritability for smoking persistence has been estimated to be in males: 59% (Li et al. 2004), and 50-71% (Tyndale, 2003), and
in females 46% (Li et al. 2004), and 4-49% (Tyndale, 2003).
Schizophrenia and nicotine addiction
Another unfounded statement, repeated by many articles, is that 80-90% of schizophrenia patients smoke (Chapman et
al. 2009). A few studies conducted in the 1980s or 1990s from Western countries, provided these very high prevalences.
However, these studies are not representative of schizophrenia patients throughout the world and reflect a point in time when
smoking was even used as reinforcement in psychiatric hospitals. Moreover, although we are convinced that the association of
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schizophrenia and smoking is very consistent across the world and that a biological explanation is likely to account for it, we
have to acknowledge that, as with any other addictive drug, nicotine addiction in schizophrenia is obviously influenced by the
availability of the drug. Therefore, the prevalence of tobacco smoking in a particular sample of schizophrenia patients is going
to be influenced by the availability of tobacco in the particular place and time at which the sample is collected. Our review of
42 samples from 20 countries provided a combined prevalence of current smoking of 62%. More important than this average
prevalence is the size of the association between schizophrenia and smoking when comparing schizophrenia patients with the
general population, that is, the effect size. This effect size is measured by a meta-analysis’ overall OR (and its CI), 5.3 (4.9-5.7)
(de Leon and Diaz, 2005). This estimated average OR is not a “true” and stable measure of the association. The worldwide
average OR has to be recalculated as new studies reflect changes in smoking prevalences in the general population of each
country, and changes in the access to tobacco of people who are going to develop schizophrenia (de Leon et al. 2007a).
The tobacco epidemic throughout the world usually passes through five stages (early, rising, peak, declining and late
stages). Different countries are usually in different stages and women tend to be at earlier stages than men. Since many people
from the US general population have quit smoking, the US is currently in the declining period. Low-income countries are
currently in the early stages (Anderson 2006). People with schizophrenia tend to be somewhat isolated from smoking reduction
trends (de Leon et al. 2002b) and, after more than 20 years of studies of people with schizophrenia in several Western
countries, most of our studies reflect very low rates of smoking cessation (<20%) in schizophrenia patients under naturalistic
conditions (i.e., without treatment), which are probably typical in the majority of psychiatric settings. Only in our most recently
published study of psychosis and smoking have we seen prevalences of smoking cessation >20% in psychotic patients (60% in
males and 28% in females). This study included Spanish patients in their early stages of psychosis who were followed for 8
years (González-Pinto et al. 2011).
Association between SMIs and addictions
The concept of SMI usually includes schizophrenia and severe mood disorders (bipolar disorder and major depressive
disorder), and may encompass nearly 3% of the US population in a one-year period (National Advisory Mental Health Council
1993). In the US, people with schizophrenia and severe mood disorders are frequently treated in the public health system.
Based on our epidemiological approach, we proposed that a shared genetic vulnerability model may explain the high
prevalence of smokers among people with schizophrenia (de Leon 1996). As further data verified that this association is
consistent throughout the world, and that the increase in smoking initiation starts before schizophrenia starts, we have come to
firmly believe that the shared vulnerability definitively reflects a genetic component (de Leon, and Diaz 2005). From a
different perspective which considers neurobiological data, Freedman and coworkers (1997) defended the view that this
association may be explained by an association of schizophrenia with genetic variations in the α7 nicotine receptor gene. This
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genetic explanation has not been empirically confirmed but, more recently, Freedman and coworkers found abnormalities in
the expression of these receptors in schizophrenia nonsmokers who were compared with controls; the abnormalities were not
present in schizophrenia smokers (Mexal et al. 2010).
The self-medication hypothesis suggests that patients with SMIs select specific drugs to treat their psychiatric
symptoms (Khantzian 1985). Schizophrenia patients usually get addicted to nicotine before their illness starts; thus it does not
seem plausible that schizophrenia patients get addicted to nicotine to treat their illness. However, we cannot rule out the
possibility that in some patients and in some circumstances patients who are smokers may smoke more to decrease symptoms
or side effects such as akathisia (de Leon et al. 2006). Other reviews have also been critical of the self-medication hypothesis
(Ziedonis et al. 2008). Prochaska and coworkers (2008) suggested that the tobacco industry’s support for this hypothesis may
explain why it has remained so popular in the literature and why other hypotheses have received less attention.
STUDY DESIGNS FOR EXPLORING SMOKING BEHAVIORS IN SCHIZOPHRENIA
This section focuses on two major issues that are crucial for designing studies of the association between
schizophrenia and smoking: the definition of smoking behaviors and the selection of controls.
Defining smoking behaviors
In a simplified way, the association between schizophrenia and tobacco smoking can mean: 1) the frequency of
smokers is higher in schizophrenia patients than in other people (“a higher percentage of them smoke”) and/or 2) schizophrenia
smokers smoke more cigarettes daily than other smokers (“they smoke more cigarettes”). More precise meanings can be given
by using testable hypotheses that compare schizophrenia patients with controls as follows: 1) “schizophrenia is associated with
an increase in smoking”, and 2) “schizophrenia is associated with increased smoking among smokers”.
Those interested in genetics should know that the genetics of current daily smoking may not be a good study target.
Current daily smoking reflects two addiction processes: 1) ever being addicted (or ever daily smoking), and 2) addiction
persistence (lack of smoking cessation in ever daily smokers). Thus the association between schizophrenia and current daily
smoking may not be particularly useful for those interested in completing genetic studies of schizophrenia and nicotine
addiction. More interesting facts are the statistical association of schizophrenia with increased frequencies of ever daily
smoking, and with decreased smoking cessation among ever daily smokers.
Selection of controls
Regarding studying control subjects, two major types of controls can be selected: non-psychiatric controls
representing the general population and patients with other SMIs. Patients with other SMIs are a better comparison group than
the general population in studies of schizophrenia patients. It is well established that psychiatric disorders are associated with
high frequencies of smoking (Hughes et al.1986; Covey et al. 1994; Lasser et al. 2000). This is particularly true for people with
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SMIs other than schizophrenia such as major depressive disorder or bipolar disorder, who exhibit greater frequencies of
smoking than non-psychiatric controls in all large US epidemiological studies (Covey et al. 1994; Lasser et al. 2000; McClave
et al. 2010). It is not surprising that only a few studies use patients with other SMIs since these studies usually have much less
statistical power than studies using non-psychiatric controls. In a 2007 US survey the difference in age-adjusted prevalences of
current smoking between schizophrenia and bipolar disorder was 12.7% (=59.1−46.4); in contrast, a difference of 40.8%
(=59.1−18.3) between schizophrenia patients and non-psychiatric controls was observed (McClave et al. 2010).
SCHIZOPHRENIA IS ASSOCIATED WITH MORE SMOKERS
This section focuses on the design of studies probing schizophrenia’s association with more smokers. Six types of
studies are possible, including those focused on: 1) an increase in current smoking with respect to the general population; 2) an
increase in current smoking with respect to other SMIs; 3) an increase in ever smoking with respect to the general population;
4) an increase in ever smoking with respect to other SMIs; 5) a decrease in smoking cessation in smokers with respect to the
general population; or 6) a decrease in smoking cessation in smokers with respect to other SMIs.
Schizophrenia is associated with an increase in current smoking when compared with the general population
As described above, the prevalences of smoking in the general population vary across time and space. They also vary
across schizophrenia patient samples, but perhaps less. Thus, it is more important to focus on effect sizes, quantifying the
difference in prevalences between schizophrenia patients and controls and its stability. Our meta-analysis showed a very strong
association between schizophrenia and current smoking (OR=5.3) (see Table 1). Was this association consistent across
countries? Yes, 40 of the 42 reviewed studies showed a significant association in the same direction (OR>1, i.e., a smoking
frequency higher in schizophrenia). Only two studies provided an OR<1: a Colombian study also showing a low prevalence of
smoking in the general population (Suarez et al. 1996), and a Japanese study with high smoking prevalences (Mori et al. 2003).
These two studies reflect a “floor effect” and a “ceiling effect”, respectively. The association between schizophrenia and
current smoking cannot be found if nobody smokes in the general population (0%, the floor), or if everybody smokes (100%,
the ceiling). Based on our experience reviewing worldwide studies (de Leon and Diaz 2005), the floor and ceiling effects may
occur at about 20% and 60% of current smoking in the general population, respectively (de Leon et al. 2007a). Thus, when
only 20% of the population are current smokers, it is difficult to find an association unless confounding variables such as
gender or educational (or socioeconomic) status are carefully controlled for and large samples are used. A Colombian
schizophrenia sample that showed no significant differences when compared with published rates for the general population
(Campo et al. 2004) became significantly different when compared with matched controls (OR=3.1, CI, 1.4-6.8) (Campo-Arias
et al. 2006). At the time of the negative Japanese study (Mori et al. 2002), few women smoked (13%) and many males smoked
(60%) in the Japanese general population. Thus, the Japanese schizophrenia study that did not show an association between
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smoking and schizophrenia (Mori et al. 2003) was contaminated by using published general population rates and not
controlling for confounders and gender differences. In fact, in that Japanese study, schizophrenia females smoked significantly
more than the general population (de Leon & Diaz, 2005), and the association between schizophrenia and smoking in male
smokers was limited by the ceiling effect of the male Japanese general population. A more recent Japanese study showed that
after controlling for confounders it was also possible to demonstrate an association between schizophrenia and smoking in
Japan (Shinozaki et al. 2010).
Changes in the smoking epidemic have been heavily influenced by gender and economic factors (Anderson 2006). To
present a simplified version of the tobacco epidemic’s chronology, it must be noted that in Western countries gender
differences were obvious in the first half of the 20th century since few females smoked, but the differences have decreased
since then. In non-Western countries, female smoking continues to be rare but is increasing, and the bulk of the tobacco
business appears to be moving to Asian males (Anderson 2006).
If one believes that gender differences in smoking are important, one needs to acknowledge that ORs using the general
population as a control are poor measures of association unless they are adjusted for gender. Nonetheless, ORs stratified by
gender may be the best way of describing the association between schizophrenia and current smoking throughout the world. In
our meta-analysis, the overall male OR for current smoking was 7.2 (Table 1). More importantly, out of the 32 studies that
provided male ORs, three provided ORs<1; however, these three studies were conducted in non-Western countries, probably
with ceiling effects. Samples matched for socioeconomic and educational status may be needed to detect the association in
countries with ceiling effects. In the meta-analysis, the overall female OR was 3.3 (Table 1). Five of the 25 studies that
provided female ORs provided ORs<1. These studies were conducted in Western countries with floor effects; again, matched
studies may be needed to detect the association (de Leon and Diaz 2005).
Schizophrenia may be associated with an increase in current smoking when compared with other SMIs
When comparing schizophrenia with other SMIs, our meta-analysis produced an overall OR of 1.9 (de Leon and Diaz
2005). The male OR was 2.3. The female OR was 1.8 but only 3 of 8 studies had significant ORs >1 (Table 1). Unfortunately,
few of the studies comparing schizophrenia with other SMIs have controlled for other addictions. In Western countries, alcohol
and drug addictions are strongly associated with current smoking. In the US and other Western countries, other addictions may
also be associated with SMIs, in general, and with schizophrenia in particular. Thus, methodologically-sound studies trying to
establish the association between schizophrenia and smoking need to control for the confounding effects of gender and
substance use disorders. Few published studies have controlled for these confounders (de Leon et al. 2002b; 2005).
Is schizophrenia associated with increased ever smoking when compared with the general population?
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The meta-analysis’ overall OR was 3.1 (de Leon and Diaz 2005). The male OR was 7.3 and the female OR was 2.8
(Table 1). The reviewed studies did not control for confounders such as level of education. In a more recent US study using
ever daily smoking as a definition of ever smoking and non-psychiatric controls, there was a significant association of ever
smoking with schizophrenia after controlling for confounders (OR=5.2; CI, 3.6-7.8) (de Leon et al. 2007a). This large OR may
be partly explained by factors associated with schizophrenia that are not well-controlled by using non-psychiatric controls (e.g.,
the presence of other addictions). Using the general population as a control does not allow the possibility of adjusting for other
addictions since other addiction levels in the general population are low and, therefore, difficult to represent in general
population samples.
By using survival analyses that were focused on age at onset of daily smoking and controlled for confounders, we
have specifically explored the timing in the association of schizophrenia with an increased initiation of daily smoking in three
studies (two in the US and one in Spain). The three studies (de Leon et al. 2002a; Gurpegui et al. 2005; Diaz et al. 2008)
replicated that: 1) when compared with non-psychiatric controls, schizophrenia was associated with a significant increase in
initiation of ever daily smoking after controlling for education and gender; and 2) non-psychiatric smokers showed a pattern of
getting addicted in their teens, with very few people getting addicted in their late 20s; in contrast, schizophrenia patients
continue to be at risk of becoming addicted after the age of 20. By focusing only on people who started daily smoking 5 years
before illness onset, two of the studies (Gurpegui et al. 2005; Diaz et al. 2008) demonstrated that the differences between
schizophrenia patients and non-psychiatric controls were not explained by the prodromal effects of schizophrenia illness. A
study of Chinese male schizophrenia patients replicated the association of schizophrenia with increased initiation of daily
smoking, by focusing on individuals who started to smoke five years before illness onset (Zhang et al. 2010).
Is schizophrenia associated with increased ever daily smoking when compared with other SMIs?
The meta-analysis overall OR was 2.0 and significant for the total and male samples but did not reach significance in
female samples (Table 1). The average rates of lifetime smoking in schizophrenia patients were 69% for the total samples, 83%
for males and 65% for females (de Leon and Diaz, 2005). These studies did not control for some confounders such as level of
education and substance use disorders. In a more recent US study of ever daily smoking, there was a significant association of
ever daily smoking with schizophrenia after controlling for confounders, OR=1.9 (CI 1.2-2.8) (de Leon et al. 2007a).
Our survival analyses of age at onset of daily smoking which controlled for confounders suggest that severe mood
disorders have an intermediate position between schizophrenia and non-psychiatric controls in the risk of becoming an everdaily-smoker, but the sample sizes were not sufficient to establish a significant difference between schizophrenia and mood
disorders (de Leon et al. 2002a; Diaz et al. 2008).
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Is schizophrenia associated with decreased smoking cessation in ever smokers when compared with the general
population?
The meta-analysis overall OR of lack of smoking cessation for the total samples of ever smokers was 5.3. The male
and female ORs were 10.0 and 2.2, respectively (Table 1). These studies did not control for other confounders. In a more
recent US study that defined smoking cessation as not smoking for one year after being an ever daily smoker, which used nonpsychiatric controls, there was a significant association between schizophrenia and a lack of smoking cessation after
controlling for confounders (OR=5.6; CI, 3.4-9.1) (de Leon et al. 2007a).
The stronger predictors of failing to quit smoking are probably heavy smoking and high nicotine dependence. As
schizophrenia is strongly associated with heavy smoking and possibly with high nicotine dependence (see next section) the
most reasonable explanation for the association between schizophrenia and lack of smoking cessation is the high levels of
nicotine dependence in schizophrenia patients. Before considering genetic factors as a possible explanation for the decreased
smoking cessation in smokers with schizophrenia, one needs to consider the association between schizophrenia and high
nicotine dependence in smokers.
Naturalistic studies indicate that smoking cessation in schizophrenia smokers is low (<10 or 20%) when no special
treatment is provided. Due to the high levels of dependence, intensive programs are needed to help schizophrenia patients to
stop smoking (Ziedonis and George 1997). According to the clinical trials literature, the only interventions that have proven to
be somewhat effective in reducing smoking in schizophrenia are bupropion and contingent reinforcement (Tsoi et al. 2010).
Is schizophrenia associated with decreased smoking cessation in ever smokers when compared with other SMIs?
The limited number of studies and their limited sample size make it difficult to draw any reliable conclusion about the
association between smoking cessation and schizophrenia when comparing schizophrenia patients with other SMIs (Table 1).
In the more recent and larger of our US studies, which used controls with other SMIs and defined smoking cessation in an ever
daily smoker as not having smoked for one year, there was no significant association between a lack of smoking cessation and
schizophrenia after controlling for confounders, (OR=1.2; CI, 0.68-2.1) (de Leon et al. 2007a).
IS SCHIZOPHRENIA ASSOCIATED WITH MORE SMOKING IN SMOKERS?
An old review (Lohr and Flynn 1992) described clinicians’ experience that schizophrenia smokers appear to smoke
more cigarettes and be more addicted than other smokers. Since then, this statement has been continuously repeated in the
literature. This section focuses on the design of studies testing the hypothesis that schizophrenia is associated with more
smoking in smokers. Four types of studies are possible, focusing on: 1) the increase in heavy smoking in schizophrenia
smokers with respect to smokers from the general population; 2) the increase in heavy smoking in schizophrenia smokers with
respect to smokers with other SMIs; 3) the high levels of nicotine dependence in schizophrenia smokers compared to smokers
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from the general population; or 4) the high levels of nicotine dependence in schizophrenia smokers compared to smokers with
other SMIs. A somewhat connected hypothesis that is reviewed in the fifth subsection is whether heavy smoking in
schizophrenia is associated with poorer prognosis in schizophrenia or not.
Is schizophrenia associated with increased heavy smoking within smokers when compared with the general
population?
Published studies have used different definitions of heavy smoking, making it impossible to provide an average OR.
However, they tend to suggest that schizophrenia smokers consistently smoke more than the smokers in the general population.
In our meta-analysis, the male ORs ranged from 2.0 to 7.4, and the female ORs from 2.0 to 8.8 (de Leon and Diaz 2005). A US
study controlling for gender, education, race and age (OR=2.9; CI, 1.5, 5.6; Diaz et al. 2008) indicated that heavy smoking was
significantly more frequent in schizophrenia smokers (42%) than in smokers without psychiatric disorders (14%).
Only a few studies have used biological methods to establish the possibility that schizophrenia smokers may have
higher nicotine metabolite levels than other smokers without psychiatric disorders (Olincy et al. 1997; Strand and Nybäck
2005; Weinberger et al. 2007; Williams et al. 2005, 2010). It may be hard to definitively establish this fact, unless large studies
of representative samples of smokers with schizophrenia and smokers without psychiatric disorders are completed and
confounders are controlled. Not surprisingly, a urine level study did not find differences after controlling for the number of
cigarettes smoked since they were controlling for smoking intensity (Bozikas et al. 2005).
Is schizophrenia associated with increased heavy smoking within smokers when compared with other SMIs?
The use of different heavy smoking definitions has made it impossible to provide an average OR when comparing
heavy smoking in schizophrenia smokers versus smokers with other SMIs. The differences tend to be small and nonsignificant, with approximately 2/3 of ORs >1 and 1/3 of them <1. In our more recent US study the prevalence of heavy
smoking within smokers was slightly higher in schizophrenia than in mood disorders (42 vs 33%), but the difference was not
significant after controlling for confounders (OR=1.6; CI, 0.94, 2.6; Diaz et al. 2008). There are no studies using biological
measures comparing smokers with schizophrenia versus smokers with other SMIs
Is schizophrenia associated with higher levels of nicotine dependence within smokers when compared with the general
population?
Studies controlling for confounders and using measures of nicotine dependence based on the FTND (Gurpegui et al.
2005; Diaz et al. 2008) indicate that schizophrenia patients who smoke are probably more dependent than smokers without
psychiatric disorders. More interesting are three small studies (Tidey et al. 2005; Lo et al. 2011; Williams et al. 2011) reporting
that when schizophrenia patients who smoke are matched to other highly dependent smokers, the former crave nicotine more;
this is something that has been suspected for years (Mckee et al. 2009; Weinberger et al. 2007).
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Is schizophrenia associated with higher levels of nicotine dependence within smokers when compared with other SMIs?
We currently have good information from several countries showing that SMIs in general are consistently associated
with higher levels of nicotine dependence than smokers from the general population (de Leon et al. 2002c, 2003; Diaz et al.
2009), but there is no definitive data showing that schizophrenia smokers smoke more or are more dependent than smokers
with other SMIs. The small observed differences and the inconsistency of the results indicate that very large samples may be
needed to settle this question.
In Western countries, heavy smoking and high nicotine dependence are also frequent in alcoholics and drug abusers.
In a study of a treatment program for quitting smoking, alcoholism and schizophrenia were associated with poor outcomes
(Gershon Grand et al. 2007). The only published comparison that we have found of nicotine dependence in smokers with
schizophrenia versus smokers treated for alcohol and/or drug addictions is a Canadian study in an inpatient unit (Solty et al.
2009). The study included 84 psychotic patients (only 73%, 62/84, with schizophrenia or schizoaffective disorder) and 31 with
primary diagnosis of addiction. The prevalences (uncorrected for gender) of current smoking were 55% and 77%, and of high
dependence (FTND≥6) were 47% and 65%, respectively (Solty et al. 2009).
Is smoking associated with worse prognosis within schizophrenia patients?
Another way of exploring the relationship between schizophrenia and heavy smoking is to compare the psychiatric
outcome of schizophrenia patients who are heavy smokers with that of schizophrenia patients who are not, controlling for other
factors that may influence prognosis. Many of the studies that provided high percentages of smoking in schizophrenia, 80-90%,
were completed in long-term hospitals. This suggests that institutionalized patients, who usually have the worst prognoses,
were more prone to smoke (de Leon and Diaz 2005). The few limited studies that have systematically explored the association
between smoking and schizophrenia outcome indicate that smokers (compared to non-smokers) or heavy smokers (compared
to mild smokers and non-smokers) tend to have poorer longitudinal prognoses (Aguilar et al. 2005; Salokangas et al. 2006;
Kobayashi et al. 2010; Wang et al. 2010; Segarra et al. 2011). Please be aware that these results go directly against the idea of
self-medication. If smoking is helpful, heavy smokers should have better prognosis than mild smokers or non-smokers. Many
more studies controlling for confounding variables are needed to establish an association between smoking or heavy smoking
in smokers and worse prognosis. If this fact is established by new studies, it may make sense to consider the hypothesis of
allostasis. Kolb and Le Moal (1997) proposed that the organism tries to counteract the effects of a given drug through a vicious
cycle in which the point where pleasure is achieved continuously changes in response to the administration of that drug. They
argue that drug addiction results from dysregulation of reward mechanisms and subsequent allostasis (chronic perturbation of
brain reward homeostasis, in which stability can only be reached through change). Following the concept of allostasis, heavy
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smoking in schizophrenia may be a no-win situation associated with a major disturbance of the brain’s compensatory systems,
which are unable to adjust themselves despite patients’ attempts to smoke heavily in order to adjust them (de Leon et al. 2005).
A PROPOSED APPROACH TO STUDYING THE ASSOCIATION BETWEEN SCHIZOPHRENIA AND SMOKING
This section begins with a summary of the complex information from epidemiological studies described in the two
prior sections; it is followed by subsections on the implications of using SMI or non-psychiatric controls in these studies, and
on our proposed study approach. Based on the above epidemiological information, we propose an approach to studying the
association between schizophrenia and ever daily smoking. The main idea is to compare schizophrenia patients with nonpsychiatric and bipolar controls by using a complex set of hierarchical hypotheses that will allow us to select consistently
associated genes.
Summary of the epidemiological literature with a focus on planning genetic studies
Table 2 briefly summarizes the data supporting an association between schizophrenia and the various definitions of
smoking behavior. In spite of the fact that there are more than 1000 articles on the subject, the only association that appears to
be definitively established is that of an increase in current smoking when compared with the general population. Unfortunately,
many of the published studies do not provide data that allow investigating other definitions of smoking behavior. In particular,
few studies report ever daily smoking rates. The limited available data suggest that for genetic studies, the best hypothesis is
that schizophrenia is associated with an increase in ever daily smoking (Table 2).
Schizophrenia is a complex trait that results from genetic and environmental etiologic influences. As a matter of fact,
it is unrealistic to consider it an etiologically homogenous entity (Kendler and Schaffner, 2011). A meta-analysis of the twin
literature indicates that schizophrenia heritability is 85% (73-90%) (Sullivan et al. 2003). The recent schizophrenia GWAS
studies support a combination of rare and common genetic variations, a major role for polygenic inheritance, and a genetic
overlap of schizophrenia and other psychiatric disorders such as bipolar disorder (Gejman et al. 2011). As smoking does not
cause schizophrenia and the association of ever daily smoking with schizophrenia appears to indicate a shared vulnerability,
this association can be used to explore a set of genes that may be associated with both schizophrenia and nicotine addiction.
Selecting SMI controls versus non-psychiatric controls
Non-psychiatric controls are likely to have much lower rates of ever daily smoking than schizophrenia patients.
According to our meta-analysis of the few studies comparing schizophrenia with the general population in Western countries,
the meta-analysis overall ORs are high, 7.3 for males, and 2.8 for females (Table 1). These large effect sizes suggest that future
studies performing this comparison will have high statistical power.
The smaller difference between schizophrenia and SMIs will provide much lower statistical power but the authors
believe that using controls with SMIs helps to eliminate some of the non-genetic confounders that may contribute to the
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association. People with SMIs and schizophrenia have been exposed to similar environments and treatments, and are not likely
to show differences in educational or socioeconomic status. Thus, according to our meta-analysis from a few studies comparing
schizophrenia with other SMIs in Western countries, the ORs we expect to find will be lower than those comparing
schizophrenia with the general population; the meta-analysis overall male OR was 2.0 and the female OR from two studies was
non-significant (Table 1).
Therefore, SMIs may be better controls than non-psychiatric subjects but their inclusion in a study as controls will
probably be accompanied by a reduction in statistical power. SMI patients used as controls may bring an additional set of
problems since they may have the genetic abnormalities associated with SMIs in general or with a specific SMI. If one believes
that including all severe mood disorders together in a genetic study is not a good idea, and that major depressive disorder and
bipolar disorder have very different genetic underpinnings, one can use only one of these two SMIs as a control group. Tables
3 and 4 provide a new review of the literature that allowed estimating the differences in ever smoking between schizophrenia
and bipolar disorder, OR=1.6 (1.1-2.2) (Table 3), and between schizophrenia and major depressive disorder, OR=1.8 (1.2-2.7)
(Table 4). These meta-analysis overall ORs were calculated using two types of studies: some were using research diagnoses
and others clinical diagnoses. Obviously a good comprehensive genetic study may benefit from the use of the more accurate
research diagnoses rather than clinical diagnoses. But it is also important to keep in mind that the studies that were used to
estimate the differences between schizophrenia and mood disorders (Diaz et al. 2009) and ORs and PARs (de Leon et al 2005)
as described in Table 5 used the less accurate clinical diagnoses.
We believe that bipolar disorder is a more reasonable choice as a control in schizophrenia studies than major
depressive disorder since it is a more homogenous concept, and is frequently associated with psychosis and chronic
antipsychotic treatment. Unfortunately, the limited data from 4 published studies indicate that increased ever smoking in
schizophrenia compared to bipolar disorder is probably small, with an average OR=1.6, which would require hundreds of
patients to prove a significant difference in a genetic factor (Table 3).
Major depressive disorder appears to be a less reasonable choice because it is a less homogenous concept than bipolar
disorder, and is rarely associated with psychosis or chronic antipsychotic treatment. On the positive side, the prevalence of
major depressive disorder in the general population is much higher than that of bipolar disorder, and the former disorder may
have a slightly weaker association with smoking than the latter. Thus, if this weaker association is true, a study using patients
with major depressive disorder may have more statistical power than a study of comparable sample size with bipolar patients.
In the majority of cases, nicotine addiction begins before depression develops (Rohde et al. 2003; 2004). In a US female twin
study, Kendler and coworkers (1993) found that ever daily smoking and lifetime major depression share some vulnerability,
which is probably explained by genetic factors. In a Swedish twin study, Edwards et al. (2011) found a similar shared genetic
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vulnerability in males, and shared genetic and unique environmental influences in females. Since in epidemiological studies the
association between major depressive disorder and nicotine addiction is weaker than that between schizophrenia and nicotine
addiction, we suspect that major depressive disorder shares a smaller amount of genetic variability with nicotine addiction than
does schizophrenia. Moreover, in our sample of US patients with SMIs, neither major depressive disorder nor bipolar disorder
were associated with ever daily smoking within patients with SMIs after correcting for other addictions (de Leon et al. 2005).
However, the association between schizophrenia and ever daily smoking was significant after controlling for addictions. Thus,
it is possible that the association between severe mood disorders (bipolar and major depressive disorders) and nicotine
addiction may merely reflect that: 1) severe mood disorders are also associated with other addictions, and 2) other addictions
are associated with ever daily smoking. Thus, the associations between severe mood disorders and ever daily smoking may not
survive the control for other addictions (Black et al. 1999; Rohde et al. 1993, 1994) and high smoking rates in severe mood
disorders may be mainly explained by comorbid addictions (Lawrence et al. 2009).
Another factor confounding the association between depression and smoking is suggested by the self-medication
hypothesis. Although we do not believe that the self-medication hypothesis satisfactorily explains the association between
schizophrenia and tobacco addiction, there is some evidence suggesting that it may explain the difficulties with smoking
cessation that depressed patients have. In non-smokers nicotine appears to be an antidepressant (Salin-Pascual et al.1996).
Tobacco smoke inhibits monoamine oxidase (MAO) activity through epigenetic mechanisms. Drugs that are MAO inhibitors
are antidepressant so it is possible that smoking may have some antidepressant effects through this inhibition (Rendu et al.
2011). Some vulnerable patients with a history of recurrent depression may become depressed when they stop smoking (Covey
et al. 1998), but not all studies agree with this hypothesis (Hitsman et al. 2003). More recently, one of the large US
epidemiological surveys suggested that patients with mood disorders are more prone to experience tobacco withdrawal
symptoms and distress (Weinberger et al. 2010); a clinical trial suggested that patients with history of depression have lower
expectations of quitting (Weinberger et al. 2011); and, according to an epidemiological study, there are complex interactions
between depression and obesity in female ever smokers (Widome et al. 2009). Twin studies indicate that psychiatric disorders,
including major depressive disorder, may worsen nicotine withdrawal, which may contribute to lower smoking cessation rates
(Xian et al. 2005; Edwards and Kendler 2011).
A study approach to searching for genes that explain the increased ever daily smoking seen in schizophrenia
Ever daily smoking may be associated with hundreds of thousands of genes of modest effects, but we are interested in
those shared with schizophrenia. Exploring the association of schizophrenia with ever daily smoking using GWAS with
millions of genetic variations may provide many false positives. To reduce the false positives due to chance, we propose to
follow a study approach that uses a set of hypotheses developed after reviewing epidemiological data. This study approach can
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be used in an exploratory GWAS with millions of genetic variations or in a more focused candidate gene approach using
thousands of genes selected a priori. Thus the design (GWAS versus candidate gene study) will determine the number of
genetic variations tested and the sample size. The recruited sample for any study testing the first-stage hypotheses can easily be
used to test the second- and third-stage hypotheses.
To best explore the genetics of the association between ever daily smoking and schizophrenia, one can use
simultaneously non-psychiatric controls and controls with other SMIs to take advantage of the progressive increase in ever
daily smoking prevalence seen from non-psychiatric controls to schizophrenia, with other SMIs (e.g., bipolar disorder) having
intermediate prevalences. The essence of our approach is that if an individual genetic variation is truly involved in the
association between schizophrenia and smoking, then we expect that this variation rejects simultaneously a set of carefully
selected null hypotheses that should be false according to epidemiological studies. Since the chance is very small that all
hypotheses are rejected simultaneously with a genetic variation that is not truly involved in the association, the type I error of a
study following our approach will be small and, therefore, the chance of obtaining many false positives is substantially
reduced. For illustration purposes, it is assumed that a nominal (uncorrected) significance level of α = 0.01 is used to test each
null hypothesis described below. This level is selected according to the preference of the investigators.
In the first stage of our approach (Figure 1), only genetic variations associated with ever daily smoking versus nonever daily smoking will be selected that are significant at the nominal level simultaneously within the non-psychiatric controls,
the bipolar disorder controls and the schizophrenia cases. That is, for a particular genetic variation, 3 null hypotheses of no
association between the genetic variation and ever daily smoking are tested, one for each of the 3 subject groups. Provided that
confounders such as gender or socioeconomic status are controlled for in the test procedure, if the genetic variation is not
involved in ever daily smoking, the probability that the 3 null hypotheses are rejected simultaneously will be at most α3 =10−6.
In the second stage of our approach (Figure 1), only those genetic variations that were significant in each of the tests
of the three above null hypotheses will be examined. The prevalence of these variations increasing the risk of smoking in
schizophrenia would have to be significantly higher in schizophrenia than in bipolar disorder and, simultaneously, significantly
higher in bipolar disorder than in controls. If a genetic variation is not involved in the association between schizophrenia and
ever daily smoking, the possibility that it is selected in both the first and second stage, that is, the possibility that it
simultaneously produces 5 significant tests is at most α5 =10−10, provided confounders have been controlled for. The reason is
that, for an irrelevant genetic variation, we do not expect that a non-significant result in the comparison of schizophrenia
patients with bipolar patients changes our nominal probability of type I error in the comparison of bipolar patients with nonpsychiatric controls.
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The positively associated gene variations that were selected in both the first and second stages will be entered into a
third stage (Figure 1). According to epidemiological findings, each of these gene variations will need to have a significantly
higher prevalence in people with schizophrenia who started daily smoking after the age of 20 than in people with schizophrenia
who had an early start (20 years or younger). According to our more recent US study with 235 schizophrenia patients (de Leon
et al. 2006; Diaz et al. 2008), we estimate that 16.6% will be never daily smokers, 58.3% ever daily smokers with early onset
of daily smoking (<20 years of age) and 25.1% ever daily smokers with late onset of daily smoking (≥20 years of age). If
appropriate confounders are controlled for, the possibility that an irrelevant genetic variation is selected simultaneously in all 3
stages will therefore be 10−12.
The prior description refers to genetic variations associated with increased risk. Protective gene variations will have
opposite patterns: 1) in the first stage, significantly lower gene-variation prevalences in ever daily smokers than in non-ever
daily smokers will be simultaneously observed within the non-psychiatric controls, the bipolar disorder controls and the
schizophrenia cases; 2) in the second stage, a significantly lower prevalence in schizophrenia than in bipolar disorder and,
simultaneously, a significantly lower prevalence in bipolar disorder than in non-psychiatric controls will be observed; and 3) in
the third stage, a significantly lower prevalence will be observed in people with schizophrenia who started daily smoking after
the age of 20 in comparison with people with schizophrenia who had an early start (20 years or younger).
Thus, although the nominal significance level for testing each individual hypothesis is 0.01, the nominal significance
level for our 3-stage approach with 6 hypotheses will be much smaller, 10−12. Since many genetic variations will be examined,
correction of p-values for multiple comparisons at each individual hypothesis testing can be performed if desired. Our
approach, however, will still reduce the final probability of type I error in this case by raising the corrected significance level to
a power of about 6, and will also produce a set of candidate genes that are meaningful from an epidemiological point of view,
not just from a statistical-significance perspective.
ASSOCIATION BETWEEN NICOTINE AND ALCOHOL ADDICTIONS
The aim of our study approach is to build a genetic psychiatric explanation of the comorbidity of schizophrenia and
nicotine addiction. To fully understand our approach, it is necessary to pay attention to other psychiatric comorbidities,
particularly alcohol and drug addictions. This section focuses on the association between nicotine and alcohol addictions and
the next one between nicotine and drug addictions.
Alcohol is widely used in many countries, although it is used in smaller proportions in the Middle East, Africa and
China (Anderson 2006; Degenhardt et al. 2008). According to the National Epidemiology Survey on Alcohol and Related
Conditions (NESARC) study in the US, the prevalence of alcohol addiction during the 12 months prior to the study was 8.5%
(12.4% in men and 4.5% in women; Grant et al. 2004).
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The following issues are reviewed below in subsections: 1) the genetics of nicotine and alcohol addiction, 2) the
association between tobacco and alcohol use in the general population, 3) the association between nicotine and alcohol
addictions in clinical samples, and 4) the association between schizophrenia and alcohol addiction.
Genetics of tobacco and alcohol use or addiction
Tobacco and alcohol use and their addictions are associated in the general population of Western countries. The use of
alcohol and tobacco may be related in two ways: 1) intrapersonal linkage (alcohol drinkers usually smoke and vice versa) and
2) situational linkage (people who use alcohol and tobacco may use them together in the same situations) (Schiffman and
Balabanis 1995). To explain these links genetic, coping, pharmacological, learning, personality and cultural factors have been
proposed (Niaura and Shiffman 1995; Bien and Burge 1990; Room 2004).

The intrapersonal linkage has interest for

geneticists. Any intrapersonal linkage has the potential of being explained by genetic factors. There is good information on the
genetics of alcohol addiction but there is less understanding on the genetics of alcohol use. Two facts are important: 1)
polymorphisms that decrease alcohol metabolism have major effects on alcohol use and therefore are protective for alcohol
addiction (they are frequent in Asian populations but rare in European and African populations) (Bierut 2011), and 2) US twin
studies indicate that familial and social factors are important determinants of alcohol use (Kendler et al. 2011). This is in
contrast with alcohol addiction, where genetic and temperamental factors are more critical (Kendler et al. 2011).
The estimates of the heritability of alcohol addiction are 51-65% in females and 48-73% in males (Tyndale 2003). It
has been suggested that genetic influences explain a substantial portion of the covariance of nicotine and alcohol addictions
(Swan et al. 1990, 1997; Lessov-Schlaggar et al. 2006). In contrast with GWAS studies of nicotine addiction, GWAS studies of
alcohol addiction have not yet provided robust findings (Bierut 2011).
Association between tobacco smoking and alcohol use in the general population
In the US, epidemiological studies have demonstrated that tobacco and alcohol addictions are associated to the point
that smoking status can be used as a possible marker of alcohol addiction (McKee et al. 2007) and that the severity of tobacco
addiction increases with the severity of alcohol addiction (Falk et al. 2006). In the National Comorbidity Survey (NCS) study
(Lasser et al. 2000), alcohol addiction was present in 22% of the general population versus 66% of ever smokers, and was
significantly associated with ever smoking. However, the analysis did not control for other psychiatric disorders. As far as we
know, there are no meta-analyses of the association between alcohol and tobacco use that summarize the epidemiological
studies throughout the world and provide an idea of this association’s variability.
Alcohol use varies widely in non-Western countries probably due to cultural and biological differences. Thus, shared
genetic vulnerability between alcohol and nicotine use should vary widely across the world. The next two paragraphs
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summarizing epidemiological studies (de Leon et al. 2005) provide support to the finding from twin studies, that non-genetic
factors may be crucial for understanding alcohol use and, therefore, its interaction with nicotine use in the general population.
When using epidemiological studies on alcohol and nicotine use as a guide for genetic studies, three keys issues must
be considered: 1) different definitions of alcohol and nicotine use (current, ever users, or quitters) may provide different results;
2) lifetime regular alcohol use (persistence of drug use) may be the best target according to what we know from addiction
genetics; and 3) any epidemiological association that is not stable over time or not replicated in various countries is not likely
to be explained by genetics. We explored the nicotine-alcohol association in the general population of two Western countries,
the US and Spain (Basque country area), over a short period of time, 1992-1996 (de Leon et al. 2007b). Some of the observed
associations were stable across the two general populations and subsamples determined by gender and race, but others were
not. Table 5 describes the strength and relevance of the association between ever smoking and lifetime alcohol use by
providing adjusted ORs and PARs.
In our study of two countries (de Leon et al. 2007b), the strength of the association between ever smoking and lifetime
alcohol use, measured by ORs, was significantly higher in the US general population than in the Basque region of Spain (Table
5). Also, there were higher PARs for the US than for the Basque country (about 80-90% versus about 60%, respectively; Table
5). Thus, in both countries tobacco smoking and alcohol use were strongly associated with each other, but the association was
significantly stronger in the US. This comparison provides an idea of the complexity of trying to explore the association of ever
smoking and lifetime alcohol use in the general population. We believe that this association may be strongly influenced by
cultural differences and that alcohol use in the general population may be influenced by non-biological factors, too. In the
Basque country, weekly drinking is a socially approved behavior. Therefore, in 1992 and 1996, alcohol drinking was much
more frequent in the Basque region of Spain than in the US (45-47% vs 22-24%, respectively). Consequently, since many
people drink socially in the Basque country, those with a vulnerability to alcohol use disorders are a minority and social
drinkers are a majority. In the US, where social drinking is less acceptable and there was more social pressure for smoking
cessation, the strong relation between ever smoking and ever drinking was probably influenced by a higher percentage of
people with higher biological vulnerability and more risk of becoming addicted (de Leon et al. 2007b). Therefore, in an
interpretation that is consistent with the results from twin studies, the association between nicotine and alcohol use is
substantially affected by cultural factors that are important in influencing alcohol use.
Association between nicotine and alcohol addictions in clinical samples
Smoking is very frequent in clinical samples of alcohol addicts but there are no meta-analyses or comprehensive
reviews of the studies. This is not surprising since researchers investigating an addiction tend to ignore addictions other than
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the one in their field of research (Kozlowski et al.1990). Published current smoking prevalences are >80% for alcohol addicts
(Hughes, 1996) and >75% for alcohol addicts in early recovery (Kalman et al. 2005).
Association between schizophrenia and alcohol addiction
Schizophrenia review articles have provided ranges of alcohol addiction prevalence of 25%–45% (Buckley 2006) or
21%–86% (Volkow 2009). More recently, Koskinen and coworkers (2009) completed a meta-analysis of studies from mainly
Western countries that indicated that approximately one-fifth of schizophrenia patients had a diagnosis of lifetime alcohol
addiction but there was a very high variability in study prevalences, a decreasing trend over years and a lack of control for
smoking effects. A more recent Swedish schizophrenia study with a large cohort indicated a prevalence of alcohol addiction of
8%, higher than in the Swedish general population (Jones et al. 2011) but lower than in US schizophrenia studies.
ASSOCIATION BETWEEN NICOTINE AND DRUG ADDICTIONS
Drugs other than alcohol and nicotine are frequently used and abused all over the world. Cannabis is used all across
the world. Opiate use is concentrated in Asia and Europe, and cocaine use is concentrated in the Americas and to a lesser extent
in Europe (Anderson 2006; Degenhardt et al. 2008). According to the NESARC study, the US prevalence of any reported drug
addiction during the 12 months prior to the study was 2.0% (2.8% in men and 1.2% in women) (Grant et al. 2004).
The following issues are reviewed in the following subsections: 1) the genetics of nicotine and drug addictions; 2) the
association between tobacco and drug use in the general population; 3) the association between nicotine and drug addictions in
clinical samples; and 4) the association between schizophrenia and drug addiction
Genetics of tobacco and drug use or addiction
Tobacco and other drugs use and their addictions are associated in Western countries. Most of the studies focused on
the association between drugs and tobacco tend to include all drugs together rather than separate specific drugs. Twin studies
support the following: 1) initiation and early patterns of drug use are strongly influenced by social and familial environmental
factors whereas later levels of use are strongly influenced by genetic factors (Kendler et al. 2008), 2) there are common genetic
influences shared by all drugs (Xian et al. 2008; Vanyukov et al. 2009), and 3) there are unique environmental and genetic
influences for specific drugs (Kendler et al. 2007; Xian et al. 2008). Kendler and coworkers (2005) commented that measures
of availability may be important but difficult to establish for illegal drugs; thus, using drug use as a measure of availability may
be practical but far from ideal. Agrawal et al. (2010) focused on the association between nicotine and cannabis addictions in a
twin study, indicating that complex bidirectional models are possible (e.g., cannabis influences tobacco, and tobacco influences
cannabis addiction).
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As drug addictions are less frequent than nicotine and alcohol addictions, there have not been large-scale GWAS
investigating drug addiction; the genetic approach has mainly focused on candidate gene studies. However, there have been
few replications (Bierut 2011).
Association between tobacco smoking and drug use in the general population
In Western countries, tobacco use and drug use are associated in the general population. Large epidemiological studies
have demonstrated that tobacco and drug addictions are associated in the US. In the 1997 National Household Survey on Drug
Abuse, Richter and coworkers (2002) found that 71% of recent illicit drug users smoked cigarettes at least once in the past
month. The adjusted smoking OR was 3.1 when comparing drug users versus the general population. Poly- versus mono-drug
users have higher prevalences of being a smoker (OR=2.4). In the NCS study, Lasser and coworkers (2000) described drug
addiction as present in 11% of the general population versus 72% of ever smokers, and was significantly associated with ever
smoking; however, they did not control for other psychiatric disorders. In the same study, Breslau and coworkers (2004a,
2004b) found that: 1) current smoking was associated with current alcohol and drug addiction after controlling for one or the
other but past smoking was not associated with them, and 2) current but not past smoking predicted subsequent onset of
alcohol and drug addiction. This suggests that there may not be a shared vulnerability between ever smoking and other
addictions, and that it is current smoking that contributes to other addictions. In an Australian epidemiological study,
Degenhardt and Hall (2001a) demonstrated that the association between smoking and current drug addictions persisted after
controlling for alcohol addiction. Moreover, smoking, alcohol and cannabis addictions appear to have independent effects en
other addictions (Degenhardt et al. 2001). A recent worldwide study indicated that it is important to accurately estimate the
stability of the interactions between alcohol and tobacco use, since it appears that the initiation of alcohol and tobacco use
interacts with the prevalence of alcohol and tobacco use to increase the subsequent onset of illicit drugs (Degenhardt et al.
2010). The effect of nicotine and alcohol use to subsequently potentiate illegal drug use has been called the gateway theory
(Wagner and Anthony 2002).
Association between nicotine and drug addictions in clinical samples
Smoking is very frequent in clinical samples of drug addicts under treatment but there are no meta-analyses or
comprehensive reviews of studies. Review articles provide estimations of current smoking prevalences >80% in drug addicts
(Hughes 1996), >75% in drug addicts in early recovery, and 80% in cocaine and opioid addicts (Kalman et al. 2005). Some
large US clinical studies reported current smoking prevalences of 75% (Budney et al.1993) and 83% (Patkar et al. 2006). After
reviewing studies in the US and the United Kingdom, Richter and Arnsten (2006) reported prevalences of 77-93%.
Association between schizophrenia and drug addiction
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We have not found meta-analyses of the association between schizophrenia and addictions to drugs in general. We
have found only a meta-analysis for one specific drug, cannabis (Koskinen et al. 2010). Cannabis use is particularly important
because there is considerable information suggesting that the secondary schizophrenia model may be partly true; cannabis may
explain some cases of schizophrenia (Van Os et al. 2010), but probably not more than 5-7% (Buckley et al. 2009).
In the 1980s, the ECA indicated that patients with schizophrenia had a lifetime history of drug addiction of 47%
(Regier et al. 1990). In a large sample of US schizophrenia patients recruited by a National Institute Health (NIH) study in the
2000s, 60% of schizophrenic patients were using substances (nicotine was not included) and 37% met criteria for alcohol or
drug addiction (Swartz et al. 2006). Westermeyer (2006) has proposed that the prevalence of lifetime addiction may have
increased up to 70-80% in US schizophrenia patients.
CONTROLLING FOR OTHER COMORBIDITIES IN OUR APPROACH
After reading the prior two sections on the interactions between nicotine addiction and alcohol/drug addictions and
between schizophrenia and alcohol/drug addiction, a legitimate question is: how much of the association between
schizophrenia and nicotine addiction is left after eliminating the effects of alcohol or drug addiction? Can the association
between schizophrenia and nicotine addiction merely reflect the association between schizophrenia and other drug addictions?
In this section, we use two pieces of information to answer this question: 1) the review of epidemiological studies and
2) one of our studies that provided adjusted ORs and PARs to measure the association between schizophrenia and ever daily
smoking. Then, a subsection puts this association in context with other psychiatric comorbidities described in this article; and
a final subsection explains how these comorbidities can be introduced in the model.
Schizophrenia and ever daily smoking after controlling for other addictions in worldwide epidemiological studies
We believe that our review of worldwide epidemiological studies (de Leon and Diaz 2005) suggests that it is not
likely that the association between schizophrenia and nicotine addiction can be completely explained by other addictions. The
association of schizophrenia with smoking is more consistent and stronger than the association of schizophrenia with other
addictions, and is more likely to be explained by a shared vulnerability model between schizophrenia and nicotine addiction.
Regarding consistency, the association between schizophrenia and nicotine addiction appears to be more consistent
around the world and has been demonstrated in non-Western countries. There is no data on the association between
schizophrenia and alcohol/drug addiction in non-Western countries.
Regarding strength, the association between schizophrenia and current nicotine addiction appears to be stronger, with
a world average prevalence of nicotine addiction of 60% (de Leon and Diaz 2005). The association between schizophrenia and
current alcohol addiction appears to be weaker, with an average prevalence of one-fifth in Western countries (Koskinen et al.
2009). The schizophrenia worldwide average is probably lower for current drug addictions but has not been studied.
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There are no large epidemiological studies in the general population studying the association between schizophrenia
and nicotine addiction after controlling for other addictions. However, in an Australian survey, Degenhardt and Hall (2001b)
studied psychotic symptoms by self-report without determining how many of the psychotic individuals had schizophrenia
and/or drug-induced psychosis. It was not surprising that alcohol and cannabis addictions and severe cases of opioid addictions
were independently associated with psychotic symptoms; all of them can cause secondary psychosis during chronic use and/or
withdrawal. Interestingly, daily smoking was also independently associated with psychosis. As tobacco does not cause
psychotic symptoms, it is possible that this association found in the Australian general population may be explained by the
association between schizophrenia and daily smoking.
Schizophrenia and ever daily smoking after controlling for other addictions in an SMI study
As far as we know, only one study in patients with SMIs has tried to control for the effects of other addictions when
examining the association between schizophrenia and nicotine addictions (de Leon et al. 2005). Moreover, this study can be
used to establish the effect sizes and relative importances of the various addictions in SMIs.
First, it is important to state that severe mood disorders, bipolar and major depressive disorder, separate or together,
were not associated with ever daily smoking in this sample of SMIs since they were much less strongly associated with
nicotine addiction than schizophrenia. We can conclude that it would not be surprising that much of the association between
mood disorders and nicotine addiction may merely reflect the high levels of alcohol and drug addiction in patients with severe
mood disorders.
Second, the association between schizophrenia and nicotine addiction was stronger and survived the control for
alcohol and drug addictions. The adjusted OR measuring the association between ever smoking and lifetime alcohol was 3.6,
and that measuring the association between ever smoking and drug use was 3.0; these numbers were somewhat higher than the
OR measuring the association between ever smoking and schizophrenia 2.0 (Table 5). Although these ORs were not
significantly different, they suggest that in an average patient with SMI it is possible that lifetime alcohol and drug addictions
are better predictors of ever daily smoking than schizophrenia. What is remarkable is that this study indicates that there was
still an ever daily smoking PAR of 21% that reflected schizophrenia effects even after correcting for other addictions. This fact
indicates to us that there is hope for a gene study on the association between schizophrenia and ever daily smoking.
Our approach in the context of other comorbidities
Schizophrenia is probably a heterogeneous disorder that is influenced by genes and environment with a 73-90%
heritability (Sullivan et al. 2003), and is probably the result of a combination of rare and common genetic variants (Gejman et
al. 2011). Schizotypy, which is frequent in schizophrenia relatives, may be a manifestation of the same genetic vulnerability
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(Nuechterlein et al. 2002; Fanous et al. 2007). Interestingly, schizotypy may also be associated with increased current smoking
(Esterberg et al. 2007; Stewart et al. 2010).
The smoking persistence heritability is 46% in females and 59% in males (Li et al. 2004) and may be explained by
thousands of genes with moderate effects (Bierut 2011). Some of these genes associated with nicotine addiction may contribute
to the increased ever daily smoking seen in schizophrenia. Our study approach to the association between schizophrenia and
smoking can help to select significant genetic variants by using a strategy developed by our knowledge of epidemiology.
In a group of patients with SMIs, the genes associated with ever daily smoking may include some that are specific to
nicotine addiction (e.g., pharmacokinetic genes) and some that are shared with lifetime alcohol addiction, lifetime drug
addiction and schizophrenia. Table 5 indicates that each of these three shared disorders may have an independent effect after
controlling for the other two and, more importantly, a relevant association between schizophrenia and ever daily smoking is left
after controlling for lifetime drug addictions (OR=2.0 and PAR=21%). The epidemiological review of the literature suggests
that shared genetic factors probably explain the association of schizophrenia with ever daily smoking. To summarize all
arguments reviewed in this article that indicate the potential for genetic studies in this area: 1) smoking does not cause
schizophrenia, 2) the consistency and strength of the association between schizophrenia and ever daily smoking around the
world is consistent with the hypothesis of a shared genetic component, and 3) the persistence of this association after
eliminating the effects of other drug addictions suggests that this association is specific and is likely to reflect a set of genes
completely different from the ones expected from a shared vulnerability to all drugs of addiction. Our model has reasonable
potential for providing gene variants associated with schizophrenia and ever daily smoking since: 1) the high frequency of ever
daily smoking in schizophrenia patients in Western countries makes the phenotype frequent and easy to study; 2) the increased
level of ever daily smoking comparing schizophrenia versus bipolar disorder and the genetic continuity between these disorders
(Gejman et al. 2011) provides a model of continuous vulnerability that can be further improved by incorporating nonpsychiatric controls to test for gene specificity; and 3) the peculiarity of schizophrenia patients who may get addicted to
nicotine in their 20s contrasts with non-psychiatric controls who do not provide further help in selecting relevant gene variants.
Table 6 compares the potential for genetic studies to examine the association between schizophrenia and ever daily
smoking with the study of other comorbidities in psychiatry. Since psychiatric disorders are essentially comorbid disorders
(Kendler et al. 2003), their comorbidity needs to be included in genetic studies. Table 6 briefly reviews 3 relevant types of
comorbidities discussed in this article: 1) ever daily smoking with other lifetime drug addictions (upper panel); 2) severe mood
disorders with ever daily smoking (middle panel); and 3) schizophrenia with other lifetime drug addictions (lower panel).
The association between ever daily smoking and lifetime alcohol addiction would be explained by a combination of
genetic and environmental factors and their interactions. The genetic factor relative weight is unknown (Table 6 upper panel).
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Similarly, the association between ever daily smoking and lifetime drug addiction would also be explained by a combination of
genetic factors, environmental factors and their interactions. Unfortunately, the association between ever daily smoking and
lifetime drug addiction should be quite difficult to study since: 1) it may include a general component and other components
specific to each drug, and 2) alcohol use is a confounding factor since it may serve as a gateway to addiction to other drugs.
Table 6’s middle panel summarizes the lesser potential for genetic studies of the association between severe mood
disorders and ever daily smoking when compared with the association between schizophrenia and ever daily smoking. The
association is: 1) less consistent and is difficult to detect in situations involving low smoking levels and floor effects (CampoArias et al. 2006); 2) weaker; and 3) perhaps explained by the association between severe mood disorders and other addictions.
Table 6’s lower panel compares the potential of genetic studies of the association between schizophrenia and ever
daily smoking with those between schizophrenia and other lifetime addictions. Studying the latter association is much more
difficult since other lifetime addictions are less frequent and the association is less consistent throughout the world. Moreover,
bidirectional relations would make the study of the association between schizophrenia and some illegal drugs such as cannabis
very complex.
Controlling for other comorbidities in the model
Using bipolar patents as controls, who tend to abuse alcohol and drugs more frequently than schizophrenia patients
(Regier et al. 1990), may help eliminate the genes shared by ever daily smoking and other lifetime addictions. Please be aware
that the second stage of our study approach looks for genes that increase the risk of daily smoking when comparing
schizophrenia with bipolar disorder. This should eliminate genes associated with other drug addictions (Table 6).
An additional way of eliminating significant genes in the first stage of our approach is to eliminate any gene that is
significantly associated with alcohol and drug addictions in the psychiatric patients. That is, after combining the samples of
schizophrenia and bipolar patients, genetic variants significantly higher in patients with addictions versus those without
addictions can be eliminated.
CONCLUSIONS
The many articles on the association between schizophrenia and tobacco smoking are limited by a lack of attention to:
1) differences between statistical associations and causal relationships, and 2) the consistency and replication of findings. This
association can be studied by: 1) focusing on current smoking, ever smoking or smoking cessation; 2) using non-psychiatric or
SMI controls; and 3) testing an increase in smoking prevalence or an increase in smoking levels within smokers. An increase in
current smoking is consistently observed in schizophrenia patients from many countries around the world when compared with
the general population, and may be demonstrated unless too few or too many smokers are present in the general population.
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Both schizophrenia and nicotine addiction exhibit high levels of heritability. The definition of smoking behavior that
has greater potential for genetic studies is ever daily smoking, since the association between ever daily smoking and
schizophrenia probably reflects a shared genetic vulnerability. Ever daily smoking may be associated with hundreds of
thousands of genes of modest effects, but according to our epidemiological data it is likely that some of them are shared with
schizophrenia and not shared with other addictions. Exploring the association of schizophrenia with ever daily smoking using a
GWAS with millions of genetic variations or a candidate gene study with thousands of genetic variations may provide many
false positives. To reduce the number of false positives due to chance, we propose to use a three-stage approach that uses six
hypotheses developed after reviewing epidemiological data. In the first stage of our approach, only genetic variations
associated with ever daily smoking versus non-ever daily smoking will be selected that are simultaneously significant within
the non-psychiatric controls, within the bipolar disorder controls and within the schizophrenia cases. Only those genetic
variations that are simultaneously significant in the 3 hypothesis tests of the first stage will be tested in the second stage. The
prevalence of these genes increasing the risk of smoking in schizophrenia would have to be significantly higher in
schizophrenia than in bipolar disorder, and significantly higher in bipolar disorder than in controls. The positively associated
and the protective genes that are simultaneously significant in the two hypothesis tests of the second stage will be introduced in
a third stage. These gene variations will need to be significantly more frequent in people with schizophrenia who started daily
smoking in their 20s (21 years or older) than in those who had an early start (20 years or younger).
Epidemiological and genetic studies suggest that nicotine addiction overlaps with alcohol and drug addictions. Using
bipolar patients as controls, who tend to abuse alcohol and drugs more frequently than schizophrenia patients, may help
eliminate the genes shared by ever daily smoking and other lifetime addictions. An additional way of filtering out unwanted
genes from the genes that were significant in the first stage is to eliminate any gene that is significantly associated with both
alcohol and drug addictions.
Psychiatric disorders are highly comorbid disorders. There is great comorbidity between SMIs and addictions and
between the various addiction types. Our study approach may be of interest for researchers in psychiatric genetics, even if they
are not particularly interested in the association between schizophrenia and smoking. We believe that any genetic approach to
psychiatric disorders may fail if comorbidity is not taken into account and careful attention is not paid to the epidemiological
studies that suggest which comorbidities are likely to be explained by genetics and which are not. Finally, we speculate that our
approach which examines the results of epidemiological studies on comorbidities and then looks for genes that simultaneously
satisfy epidemiologically-suggested sets of hypotheses, may also apply to the study of other major illnesses, such as cancer,
diabetes, or autoimmune diseases, in which a mosaic of non-secondary comorbidities is usually present.
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Table 1. Summary of meta-analysis (de Leon and Diaz, 2005) on the association between schizophrenia and different smoking behaviors: odds ratios (ORs) and consistency
Study consistencya
Countries
Average ORs ( 95% CI)
N
OR>1 +Significant
Nb
Typec
Total sample
Male
Female
↑ Current smoking vs general population
42
40/42 37/42
20
Some non-Western
5.3 (4.9-5.7)
32
29/32 29/32
18
Most Western
7.2 (6.1-8.3)
25
20/25 20/25
15
Most Western
3.3 (3.0-3.6)
↑ Current smoking vs other SMIs
18
17/18 14/18
9
Most Western
1.9 (1.7-2.1)
14
11/14 11/14
8
Most Western
2.3 (2.0-2.7)
8
6/8
3/8
5
Western
1.8 (1.5-2.3)
↑ Ever smoking vs general population
9
8/9
8/9
6
Western
3.1 (2.4-3.8)
4
4/4
3/4
3
Western
7.3 (1.04-13.6)
3
3/3
2/3
3
Western
2.8 (1.2-4.4)
↑ Ever smoking vs other SMIs
5
4/5
3/5
5
Most Western
2.0 (1.6-2.4)
4
4/4
2/4
3
Most Western
2.0 (1.5-2.7)
2
1/2
0/2
2
Western
0.92 (0.44-1.9)
↓ Smoking cessation in ever smokers
6
6/6
6/6
5
Western
5.3 (4.2.-7.1)
vs general population
4
4/4
4/4
3
Western
10.0 (7.1-16.7)
3
3/3
2/3
3
Western
2.2 (1.5-4.3)
↓ Smoking cessation in ever smokers
4
3/4
1/4
4
Western
1.8 (1.1-3.0)
vs other SMIs
4
4/4
3/4
3
Most Western
2.9 (1.9-13.4)
2
0/2
0/2
2
Western
0.37 (0.11-1.3)
CI: 95% confidence interval.
a
Consistency includes N: number of studies. OR>1: number of individual studies with OR >1 divided by N. +Significant: number of individual studies with significant OR
>1 divided by N.
b
N: number of countries.
c
Type: USA, Canada, Europe and Israel are considered Western countries.
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Table 2. Association between smoking behaviors and schizophrenia: a summary focused on various definitions and their potential for genetic studies
Smoking behavior definition
Control
Results
Potential
↑ Current daily smoking
General population
Very strong and consistent association worldwide
Complex: ↑initiation and/or ↓ cessation
Other SMIs
Good, but limited data from non-Western countries
Complex: ↑initiation and/or ↓ cessation
↑ Ever daily smoking

General population
Other SMIs

Good, but no data from non-Western countries
Supported by very few Western studies

Differences partly due to SMI confounders
Best potential

↓ Cessation in daily smokers

General population
Other SMIs

Supported by very few Western studies
No data in favor: it may not be true

Differences may be due to heavy smoking
No proof of association

↑ Heavy smoking in daily smokers General population
Other SMIs

Supported by a few Western studies
Few inconsistent studies

Differences partly due to SMI confounders
No proof of association

↑ Nicotine dependence in smokers General population
Other SMIs
SMI: severe mental illness.

Supported by a few Western studies
Few inconsistent studies

Differences partly due to SMI confounders
No proof of association

43
Table 3. Odds ratios (ORs) comparing frequencies of ever smoking in patients with schizophrenia versus bipolar disorder.
Author
Country
Type
Schizophrenia
Bipolar disorder
OR
CI
EVER SMOKING IN SAMPLES INCLUDING BOTH GENDERS
Dome et al. 2005
Hungary
Outpatients
75% (91/122)
70% (42/60)
1.3
(0.63, 2.5)
Itkin et al. 2001
Israel
Outpatients
55% (35/64)
60% (42/70)
0.83
(0.40, 1.6)
de Leon et al. 2002a
USA
Inpatients
91%(62/68)
83% (24/29)
2.1
(0.59, 7.7)
Diaz et al. 2009
USA
In/outpatients
83% (215/258)
74% (73/99)
1.8
(1.02, 3.1)
Total of 4 samples
3 Countries
79% (403/512)
70% (181/258)
1.6
(1.1, 2.2)
EVER SMOKING IN MALES
Dome et al. 2005
Hungary
Outpatients
74% (46/62)
77% (20/26)
0.83
(0.29, 2.5)
Itkin et al. 2001
Israel
Outpatients
71% (22/31)
62% (20/32)
1.5
(0.50, 4.2)
de Leon et al. 2002a
USA
Inpatients
95% (41/43)
88% (14/16)
2.9
(0.37, 25.0)
Diaz et al. 2009
USA
In/outpatients
86% (127/148)
87% (40/46)
0.91
(0.34, 2.4)
Total of 4 samples
3 Countries
83% (236/284)
78% (94/120)
1.4
(0.77, 2.3)
EVER SMOKING IN FEMALES
Dome et al. 2005
Hungary
Outpatients
75% (45/60)
65% (22/34)
1.6
(0.67, 4.0)
Itkin et al. 2001
Israel
Outpatients
39% (13/33)a
58% (22/38)
0.48
(0.18, 1.22)
de Leon et al. 2002a
USA
Inpatients
84% (21/25)
77% (10/13)
1.6
(0.29, 8.3)
Diaz et al. 2009
USA
In/outpatients
80% (88/110)
62% (33/53)
2.4
(1.2, 5.0)
Total of 4 samples
3 Countries
73% (167/228)
63% (87/138)
1.6
(1.0, 2.5)
CI: 95% confidence interval.
a
The study included a small subsample of female schizophrenia patients with an unusual ethnic background who smoked less than the Israeli female general population.
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Table 4. Odds ratios (ORs) comparing frequencies of ever smoking in patients with schizophrenia versus major depressive disorder.
Author
Country
Type
Schizophrenia
Major depressive disorder
EVER SMOKING IN SAMPLES INCLUDING BOTH GENDERS
Dome et al. 2005
Hungary
Outpatients
75% (91/122)
70% (64/92)
de Leon et al. 2002a
USA
Inpatients
91% (62/68)
73% (16/22)
Diaz et al. 2009
USA
In/outpatients
83% (215/258)
75% (50/67)
Total of 3 samples
2 Countries
82% (368/448)
72% (130/181)
EVER SMOKING IN MALES
Dome et al. 2005
Hungary
Outpatients
74% (46/62)
75% (24/32)
de Leon et al. 2002a
USA
Inpatients
95% (41/43)
87% (13/15)
Diaz et al. 2009
USA
In/outpatients
86 % (127/148)
74% (17/23)
Total of 3 samples
2 Countries
85% (214/253)
77% (54/70)
EVER SMOKING IN FEMALES
Dome et al. 2005
Hungary
Outpatients
75% (45/60)
67% (40/60)
de Leon et al. 2002a
USA
Inpatients
84% ( 21/25)
43% (3/7)
Diaz et al. 2009
USA
In/outpatients
80% (88/110)
75% (33/44)
Total of 3 samples
2 Countries
79 % (154/195)
68% (76/111)
CI: 95% confidence interval.

OR

CI

1.3
3.9
1.7
1.8

(0.70, 2.3)
(1.1, 13.6)
(0.90, 3.2)
(1.2, 2.7)

0.96
3.2
2.1
1.6

(0.36, 2.6)
(0.40, 24.7)
(0.76, 6.0)
(0.85, 3.1)

1.5
7.0
1.3
1.7

(0.68, 3.3)
(1.1, 44.1)
(0.58, 3.0)
(1.02, 2.9)

45
Table 5. Adjusted odds ratios (ORs), their confidence intervals (CIs) and population attributable risks (PARs) for ever smoking1
Factor
Adjusted OR (CI)
Prevalence (P)
PAR
IN THE GENERAL POPULATION (de Leon et al. 2007b)2
Lifetime alcohol use (USA, 1992)
6.2 (4.4-8.8)
88%
82%
Lifetime alcohol use (USA, 1996)
9.8 (7.5-12.8)
88%
89%
Lifetime alcohol use (Basque country,3 1992)
3.0 (2.3-3.9)
86%
63%
Lifetime alcohol use (Basque country,3 1996)
2.6 (2.1-3.3)
83%
57%
IN PATIENTS WITH SEVERE MENTAL ILLNESS (SMI) (N=550; de Leon et al. 2005)3
Lifetime alcohol use disorder
3.6 (2.2, 6.0)
64%
52%
Lifetime drug use disorder
3.1 (1.8, 5.4)
52%
38%
Schizophrenia
2.0 (1.3, 3.2)
28%
21%
High school or lower educational level
2.1 (1.3, 3.3)
71%
33%
Non-obesity (BMI<30)
1.6 (2.6, 1.04)
54%
17%
1
In patients with SMI, ever smoking was defined as ever daily smoking (clinical definition). In the general population, ever smoking also included non-daily smokers, so the
definition was slightly wider (epidemiological definition). A prior article described the differences and overlap between these two definitions (Diaz et al. 2009).
2
For data from the general population, the population attributable risk was computed as (P/100) × (OR−1)/{(P/100) × (OR−1)+1} (Bolton and Robinson 2010).
3
Basque country is located in the North of Spain.
4
In patients with severe mental illness, the population attributable risk for a particular factor was adjusted for the other described factors. Covariate-adjusted attributable
risks were computed by using Stata' aflogit command (StataCorp 2009; Greenland and Drescher 1993).
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Table 6. Comparing the potential for genetic studies of the association of schizophrenia with increased ever daily smoking with other associations
Association
Comparison
Cultural issues
Genetic component
ASSOCIATION OF EVER DAILY SMOKING WITH OTHER LIFETIME ADDICTIONS
Ever daily smoking with lifetime alcohol addiction Stronger and probably consistent in Western counties Very important in alcohol use
Unknown
Very complex with bidirectional components
Ever daily smoking with lifetime drug addiction

Stronger
Drug access varies by world region Unknown
Probably consistent in Western countries
Common/specific components for each drug
Confounded by alcohol use/addiction
ASSOCIATION OF SEVERE MOOD DISORDERS WITH EVER DAILY SMOKING
2
Bipolar disorder with ↑ever daily smoking
Weaker and less consistent
Subject to ceiling/floor effects1
No primary?
Possibly explained by ↑ other lifetime addictions
2
Major depressive disorder with ↑ever daily smoking Weaker and less consistent
Subject to ceiling/floor effects1
No primary?
Possibly explained by ↑ other lifetime addictions
ASSOCIATION OF SCHIZOPHRENIA WITH OTHER LIFETIME ADDICTIONS
Schizophrenia with ↑ lifetime alcohol addiction
Weaker and less consistent
Some countries no alcohol access Unknown
Confounders not studied
Complex definition3

Schizophrenia with ↑ lifetime drug addiction

1

Weaker and less consistent
Drug access varies by world region Difficult to study
Bidirectional components
Confounded by ↑ tobacco and alcohol use/addiction

The association between schizophrenia and increased (↑) ever daily smoking is also subject to ceiling and floor effects, but bipolar and major depressive disorders may be
more susceptible to these effects (Campo-Arias et al. 2006).
2
No primary?: current limited information suggests that the association between bipolar/major depressive disorder with increased lifetime addictions may explain the
increase in ever daily smoking seen in these severe mood disorders. Thus, studying the genes associated with bipolar/major depressive disorder with increased ever daily
smoking may reveal genes contributing to the association of bipolar/major depressive disorder with increased lifetime addictions.
3
Twin studies suggest that genetic effects are important in alcohol dependence (Ystrom et al. 2011). When the phenotype is modified to include other less severe
phenotypes of alcohol addictions (such as those seen in people with schizophrenia), these milder forms of alcohol addiction may reflect different genetic factors (Dick et al.
2011) than those associated with alcohol dependence.
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Figure 1. Schematic representation of a proposed three-stage approach for searching genes explaining the
increased risk of ever daily smoking seen in schizophrenia
STAGE 1: Are the genetic-variation frequencies significantly higher1 in ever daily smokers than in non-ever daily
smokers within…
Non-psychiatric
(NP) controls?
(Hypothesis 1)

and

Bipolar (BP)
controls?
(Hypothesis 2)
Question 1

and

Schizophrenia
(S) cases?
(Hypothesis 3)
3)3)(Qestion

If
Yes
to
All

STAGE 2: Do genetic-variation frequencies significantly satisfy the inequality1…
S cases > BP controls?
(Hypothesis 4)

and

BP controls > NP
controls?
(Hypothesis 5)

If
Yes
to
All

STAGE 3: Within schizophrenia ever-daily smokers, do genetic-variation frequencies significantly satisfy the
inequality1…

Late onset > early onset of
ever daily smoking?2
(Hypothesis 6)
If
Yes
to
All

Genetic variation may significantly contribute to
the association between schizophrenia and
ever daily smoking.

1The

figure describes gene variations that are risk factors for an increased risk of ever daily smoking. For
associated protective genes, the frequency inequalities in the 3 stages will exhibit the opposite pattern. Protective
genes will exhibit 1) lower frequencies in ever daily smokers than in non-ever daily smokers within non-psychiatric
controls (hypothesis 1), bipolar controls (hypothesis 2), and schizophrenia cases (hypothesis 3); 2) lower
frequencies in schizophrenia cases than in bipolar controls (hypothesis 4), and in bipolar controls than in nonpsychiatric controls (hypothesis 5); and 3) lower frequencies in late onset than in early onset schizophrenia daily
smokers (hypothesis 6).
2Late onset of ever daily smoking: ≥20 years of age. Early onset of ever daily smoking: <20 years of age.

